国際医薬品開発研究ジャーナル

  • ISSN: 0975-9344
  • ジャーナル h-index: 44
  • 雑誌引用スコア: 59.93
  • ジャーナルのインパクトファクター: 48.80
インデックス付き
  • Genamics JournalSeek
  • 中国国家知識基盤 (CNKI)
  • サイテファクター
  • シマゴ
  • 研究ジャーナル索引作成ディレクトリ (DRJI)
  • OCLC-WorldCat
  • パブロン
  • ミアル
  • 大学補助金委員会
  • ユーロパブ
  • Google スカラー
  • シェルパ・ロメオ
  • 秘密検索エンジン研究所
  • リサーチゲート
このページをシェアする

抽象的な

Exposing Profound Screening Potential of Ethanol-Based Dissolution Media in the Development of Oral-Modified Dosage Forms

Berginc Katja , Huzjak Tilen, Lavrič Olivera, Buzeti Uroš, Jordan Vanja, Velušček Dejan

Characterization of drug release from modified-release products in the presence of alcohol is required to evaluate the possibility of dose dumping due to safety assurance reasons. A generic product containing BCS IV drug and HPMCAS polymer was formulated as amorphous solid dispersion with hot-melt extrusion having the same qualitative and quantitative composition as the reference product. Although formulations were bioequivalent, they exerted different vulnerability towards ethanol, and the root cause was sought to establish appropriate control during product life cycle. To identify critical process parameters (CPPs) and critical material attributes (CMAs) according to the Quality by Design, a systematic screening of excipient properties and process parameters was performed. The indepth evaluation revealed that dose dumping could be avoided with appropriate selection of specification limits for binder viscosity and particle size, specific surface area of the glidant and adjustments in the milling and tableting parameters. Due to the effective prevention of dose dumping, additional changes in qualitative or quantitative composition of the generic product were not required; thus subsequent bioequivalence study was not warranted.

Keywords:Dose-Dumping; Critical Material Attributes; Critical Process Parameters; Microfluxtm; Bioequivalence; Hot-Melt Extrusion

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません